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Biallelic inactivation of ATM gene causes the rare autosomal recessive disorder Ataxia-Telangiectasia 
(A-T). Female relatives of A-T patients have a two-fold higher risk of developing breast cancer (BC) 
compared with the general population. ATM mutation carrier identification is laborious and expensive, 
therefore, a more rapid and directed strategy for ATM mutation profiling is needed. We designed a 
case-control study to determine the prevalence of 32 known ATM mutations causing A-T in Spanish 
population in 323 BRCA1/BRCA2 negative hereditary breast cancer (HBC) cases and 625 matched 
Spanish controls. For the detection of the 32 ATM mutations we used the matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) technique. We identified 
one patient carrier of the c.8264_8268delATAAG ATM mutation. This mutation was not found in the 
625 controls. These results suggest a low frequency of these 32 A-T causing mutations in the HBC 
cases in our population. Further case-control studies analyzing the entire coding and flanking 




Hereditary Breast Cancer, ataxia-telangiectasia, ATM, BRCA1, BRCA2, case-control study, MALDI-
TOF mass spectrometry.  
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Breast cancer (BC) is the most frequently diagnosed cancer among western women. 
Approximately 7% of BC cases are of hereditary origin [1]. To date, several BC susceptibility alleles 
have been identified and categorized into three groups according to their population frequency and the 
risks conferred: rare high-penetrance alleles, moderate-penetrance alleles, and common low-penetrance 
alleles [2]. The BRCA1 and BRCA2 genes are the two major predisposition high penetrance genes to 
BC conferring a risk that is 10-to 30-times the risk among women in the general population. However, 
germline mutations in these genes only account for up to 16% of the hereditary breast cancer (HBC) 
burden [3]. Mutations in other BC predisposing high-penetrance genes such as TP53, STK11, CDH1, 
PTEN and lately RAD51C [4] are also associated with HBC, but each one has a small contribution to 
familial BC (1%) except for patients with specific features or in the context of rare cancer syndromes 
[5,6]. Recently published genome-wide association studies provide evidence for low-penetrant BC 
susceptibility loci that confer a small relative risk up to 1.5-fold and an overall 8% of the HBC risk [7]. 
A third group known as moderate-penetrance BC genes confers increased risks of two to fourfold 
compared to the 10% risk in the general population. Thus far, five moderate-risk BC genes have been 
convincingly identified: CHEK2, BRIP1, PALB2, NBS1, and ATM [8].  
 The ATM gene (ataxia telangiectasia mutated; MIM#607585) encodes a lipid kinase 
phosphatidylinositol 3-kinase (PI3K) expressed in a wide range of tissues. It is the key player of a 
signaling cascade that detects and repairs DNA double-strand breaks, a cascade in which the BRCA1 
and BRCA2 proteins are involved [9]. Biallelic inactivation of ATM gene causes the rare autosomal 
recessive disorder Ataxia-Telangiectasia (A-T), a neurodegenerative disorder characterised by 
progressive cerebellar ataxia and dysarthria, associated with ocular telangiectasia, immunodeficiency, 
sensitivity to ionising radiation, and an increased risk of cancers, especially leukaemias and lymphomas 
[10]. Most of the patients with A-T are compound heterozygotes (inheriting distinct ATM mutations 
from each parent) and over 70% of these mutations are base substitutions, small insertions or deletions 
and splicing alterations that generate premature termination codons which in turn result in a truncated 
and unstable ATM protein (see http://chromium.liacs.nl/LOVD2/home.php?select_db=ATM) [11]. The 
prevalence of such ATM mutations has been shown to be as high as 0.5–1% in Western general 
populations [12]. The link between A-T and BC arouse from clinical and epidemiological studies 





was definitively confirmed in a case-control study by Renwick et al [16]. The authors analyzed 443 
cases of familial BC and 521 controls, and found 12 women carrying an ATM mutation in the case 
group (2.70%) and two in the control group (0.38%). They estimated that ATM mutation heterozygosity 
was associated with a BC relative risk (RR) of 2.37 (95% CI: 1.51–3.78). Our group [17] reported the 
first results of ATM germline mutations in Spanish population with early-onset BC and showed that one 
of 43 patients (2.3%) had a deleterious truncating ATM mutation (c.3802delG) that causes A-T in the 
homozygous state. 
Despite all this evidence, the large size of ATM (it contains 63 exons spanning approximately 
150 kb of genomic DNA) and its very heterogeneous mutational spectrum makes mutation carrier 
identification laborious and expensive. Hence a rapid and more directed strategy for ATM mutation 
profiling is needed. Founder effects for ATM mutations have been reported in different countries, 
including Spain [18-20]. All the 13 ATM mutations identified by Renwick et al [16] were predicted to 
cause A-T, and nine of those identified in cases have previously been reported in A-T families, 
including the two most common mutations in the UK, c.5762ins137 and c.3802delG. More recently, a 
study of Bogdanova et al [21] provided evidence for the association of an ATM founder mutation 
(c.5932G>T; p.E1978X, a common A-T causing mutation) with BC in Eastern European populations. 
These findings suggest that it is possible to approach carrier testing by first identifying the most 
common mutations in selected populations and then developing rapid assays that use small amounts of 
genomic DNA and less costly methods.  
 The goal of our study was to confirm the implication of ATM as a susceptibility gene in 
BRCA1/BRCA2 wild-type HBC Spanish families. We designed a case-control Spanish HBC study to 
determine the prevalence of known ATM mutations causing A-T in Spanish populations using the 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) 
technique. 
Patients and Methods  
Patient samples 
Genomic DNA was available from index cases of 323 BRCA1 and BRCA2 wild-type Spanish 
HBC families from two distinct populations of Spanish origin: Catalonian and Galician. The 228 










cancer genetics clinics of the Catalan Institute of Oncology, University Hospital Vall d’Hebron, and 
Santa Creu i Sant Pau Hospital from Barcelona, Catalan Institute of Oncology of Girona and Sant Joan 
University Hospital of Tarragona. The 95 Galician HBC cases had previously been studied by Blanco 
et al for germline mutations in TP53 and PTEN [22]. All participants provided written informed 
consent and the study was approved by the institutional review boards. DNA samples from up to 625 
geographically matched Caucasian Spanish controls (426 from Catalonia and 199 from Galicia) 
without personal or familial antecedents of any cancer were also analysed to establish the frequency of 
the 32 selected mutations in each respective population. DNA was quantified using NanoDrop 1000 
spectrophotometer (Thermo Scientific, Wilmington, USA) and diluted to a final concentration of 20 
ng/ul for genotyping. 
 
ATM mutation selection  
We analyzed 32 ATM mutations responsible for A-T in Spanish population previously 
described by Mitui M. et al [18], Castellví-Bel et al [20] and García Pérez et al [23], together with the 
ATM mutation and the likely deleterious variants reported previously by our group in early-onset BC 
Spanish patients negative for BRCA1/2 mutations [17] (Table1). 
 
Genotyping 
Mutation screening of the 32 mutations was performed at the Spanish National Genotyping 
Center in the node of Santiago de Compostela by MALDI-TOF MS using the Sequenom MassArray 
System and iPLEX Gold genotyping chemistry. The design of oligonucleotides was carried out 
according to the guidelines of Sequenom and performed using MassARRAY Assay Design software 
(version 1.0). Mutations detected were confirmed by bi-directional sequencing with “Big Dye 
Terminator v3.1 Cycles Sequencing kit” (Applied Byosistems, Warrington, UK) on ABI PRISM 
3730xl Genetic Analyzer (Applied Biosystems) in accordance with the manufacturer’s instructions. 
Primer sequences are available on request. Sequences were examined using Staden Package software 
(Open Source Technology Group, Inc.). 
 





In the current study we analyzed the presence of 32 ATM mutations in BRCA1/BRCA2 
negative Spanish HBC samples using MALDI-TOF mass spectrometry technology. The genotyped 
mutations were selected since were known to be responsible for A-T in Spanish populations. 
We identified the mutation c.8264_8268delATAAG in heterozygous state in a Catalonian 
woman with BC at the age of 34 (Figure 1A-B). The patient had two first degree relatives diagnosed 
with BC at the ages of 58 and 66, but none sample was available from these patients. The mutation was 
confirmed by direct sequencing (Figure 1C). No other mutations were found in control or case samples. 
Interestingly, c.8264_8268delATAAG had previously been identified in one Spanish, one Costa Rican, 
and three Brazilian A-T patients with different STRs and SNPs haplotypes, suggesting that these 
represent independent mutational events or a hot-spot in the ATM gene [18]. 
The utility of genetic testing of BC genes has comprehensively been shown for BRCA1 and 
BRCA2 genes [24]. The demonstration that ATM mutations predispose to BC [16] could also be used in 
risk stratification of women to allow them to make changes on their medical surveillance and lifestyle 
habits to reduce their risk of BC. Nevertheless, it is not yet known what determines which women with 
ATM mutations will develop BC (around 15 per cent of female ATM carriers) [25] and this limits the 
clinical utility of identifying such mutations. Moreover, the significance of most ATM missense 
variants is unknown and only a few of them have been considered to be pathogenic. Recently, Fletcher 
et al [26] showed that the combined effects of five missense ATM SNPs were associated with a small 
increased risk of BC, explaining an estimated 0.03% of the excess familial risk of BC. Tavtigian et al 
[27] used an in silico missense-substitution analysis to assess the contribution to BC risk of rare ATM 
variants described in seven published ATM case-control studies and from their own mutation screening 
data of additional case-control analyses. They provided evidence that a subset of rare missense ATM 
substitutions confer increased BC risk. An analysis on a subset of these rare variants lead them to 
propose the hypothesis that the missense mutations conferring increased risk of BC are more 
concentrated in the last third of the ATM protein (FAT, kinase, and FATC domains) and that a subset 
of these missense substitutions actually confer higher risk of BC than do protein-truncating variants on 
average. Moreover, if ATM mutations act multiplicatively with other genetic BC factors it may be 
possible to identify women with combinations of BC susceptibility alleles, which all together give risks 





ATM mutation status may also be of relevance for the treatment of BC due to its influence on 
response to radiation, as it has recently been suggested in a nested case-control study within a cohort of 
52,536 survivors of unilateral BC. Women who carried deleterious ATM variants and who were treated 
with radiation had a statistically significantly higher risk of contralateral BC [28]. 
Together, these data reveal that ATM truncating variants, as well as a number of missense 
variants confer BC risk. However, their prevalence is usually low and their variety may differ widely 
among populations from different geographical or ethnic origins. Therefore, taking the complexity and 
size of the gene into account, specific analysis approaches are necessary by using reliable, flexible, and 
rapid methodologies. 
Several methods have previously been used to screen for ATM mutations in order to overcome 
the complexity of analyzing ATM gene, such as a non-isotopic RNase cleavage-based assay (NIRCA) 
[29], Denaturating Gradient Gel Electrophoresis (DGGE) [30], single-strand conformational 
polymorphism (SSCP) [31], denaturing high-performance liquid chromatography (DHPLC) [32] and 
more recently, enhanced mismatch mutation analysis (EMMA) [33]. Despite the availability of all 
these techniques for ATM analysis, Sanger sequencing of the entire coding and flanking sequences of 
ATM gene remains standard making ATM mutation identification expensive and labour intensive.  
We analyzed in BRCA1/BRCA2 negative Spanish HBC samples a panel of 32 ATM mutations 
previously found in A-T Spanish patients using MALDI-TOF mass spectrometry. In our hands, this 
methodology was technically successful to study this set of ATM selected mutations. Nevertheless, the 
predictive power of our approach is low due to the small frequency of the 32 mutations found in the 
323 BRCA1 and BRCA2 wild-type Spanish women with HBC with a prevalence of 0.31% (1/323; 95% 
CI 0.008-1.71). The practicability and flexibility of this technology allow the addition of new ATM 
mutations in the design, which could improve its efficiency in the future. Hence, further case-control 
studies are warranted analysing the whole coding sequence of ATM in Spanish BC patients. 
Future steps in moderate-risk BC genes mutation profiling, such as ATM, will probably 
require a comprehensive strategy by full sequencing of the genome applying massive parallel “next 
generation” sequencing procedures. Preliminary reports [34] suggest that this sequencing technology 
would enable accurate and cost-effective full screening of a large number of predisposition genes 
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Figure 1: Analysis of c.8264-8268delATAAG ATM mutation.  
A. Genotyping calls for c.8264-8268delATAAG. Sample carrying the deletion in heterozygous state is 
indicated by a green square, while those without the deletion are displayed as blue triangles.  
B. Sequenom mass spectrum for the mutation c.8264-8268delATAAG. The top figure indicates the 
wild-type allele, while the bottom one indicates both, wild-type and c.8264-8268delATAAG mutation 
alleles.  
C. Direct sequencing of the ATM c.8264_8268delATAAG carrier sample. The arrow shows the start 
point of the nucleotides deletion. 
 
Table Legends 
Table 1: ATM mutations (n=32) previously described in A-T Spanish patients and genotyped in our 
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ATM mutations (n=32) previously described in Spanish population and 




Nomenclature in the 
original reference 







640delT c.640delT p.Ser214ProfsX16 18 
715delT c.716delT p.Phe239SerfsX16 18 
IVS15-2A>C c.1899-2A>C p.Cys633X 23 
2250G>A c.2250G>A p.Glu709_Lys750del 18 
2413C>T c.2413C>T p.Arg805X 18 
IVS21+1G>A c.2921+1G>A p.(?) 18 
IVS21+1G>CA c.2921+1delinsCA p.Tyr947GlnfsX9 23 
3712_3716delTTATT c.3712_3716delTTATT p.Leu1238LysfsX6 18 
3763T>G c.3763T>G p.Leu1255Val 17 
3802delG c.3802delG p.Val1268X 17 
3836G>A c.3836G>A p.Trp1279X 18 
3894_3895insT c.3894dup p.Ala1299CysfsX3 18 
IVS28+1711del3450 c.3994-1415_4270 p.(?) 18 
IVS33+2T>C c.4776+2T>C p.(?) 18 
5188C>T c.5188C>T p.Arg1730X 18 
5644C>T c.5644C>T p.Arg1882X 18 
6314G>C c.6314G>C p.Arg2105Thr 17 
6342_6343insC c.6342dup p.Val2115ArgfsX12 18 





7653T>C c.7653T>C Synonymous 17 
8100A>T c.8100A>T p.Lys2700Asn 18 
8103_8104delAA c.8103_8104delAA p.Ile2702ArgfsX15 18 
8156G>A c.8156G>A p.Arg2719His 17 
8177C>T c.8177C>T p.Ala2726Val 18,20 
8264_8268delATAAG c.8264_8268delATAAG p.2718_2756del39 18 
8283_8284delTC c.8283_8284delTC p.Gln2762AlafsX6 18 
IVS62+1G>A c.8786+1G>A p.Gly2891AspfsX9 23 
8875_8878delGACT c.8875_8878delGACT p.Asp2959GlyfsX3 18 
8977C>T c.8977C>T p.Arg2993X 18 
c.9008del28 c.9008_9035del p.Lys3004TyrfsX5 23 
c.9010_9037del28 c.9010_9037del p.Lys3004TyrfsX5 18,20 
c.9170_9171delGA c.9170_9171delGA p.X3057PhefxX5 18 
 
 
 
